Niegowska Joanna, Kucharska Alicja, Gajewska Danuta
Katedra Dietetyki, Wydział Nauk O Żywieniu Człowieka I Konsumpcji, SGGW, Warszawa, Polska.
Zakład Żywienia Człowieka, Warszawski Uniwersytet Medyczny, Warszawa, Polska.
Wiad Lek. 2017;70(2 pt 2):335-339.
Hyperuricemia and gout are a growing health problem worldwide. Their etiology is complex, and usually caused by excessive production of uric acid and/or impaired excretion. Some drugs used in the treatment of high blood pressure furthermore increase the risk of hyperuricemia. An additional risk factor for hyperuricemia is obesity. Thus far, there is no consensus on the treatment of patients with asymptomatic hyperuricemia, despite a large number of studies conducted worldwide.
To evaluate the prevalence of hyperuricemia among patients with essential hypertension and obesity, pharmacologically treated with combination therapy.
A total of 109 obese patients (mean BMI=34.6±3.5 kg/m2) were included in this study, selected from the outpatients at the Clinic of Arterial Hypertension, the unit of the Cardinal Stefan Wyszyński Institute of Cardiology in Warsaw. Patients were treated with at least two antihypertensive drugs. Blood pressure, uric acid and insulin levels were measured among patients.
The average systolic blood pressure and diastolic blood pressure were of 131±5,9 and 84.6±3.6 mmHg respectively, the average uric acid level of 6.4±1.5 mg/dl, and the average level of insulin 17.6±11.0 mU/L. Hyperuricemia was found in 33 patients (27.5% of subjects). The uric acid level was significantly higher among men. A positive correlation between the serum uric acid concentration of serum insulin (r = 0.27, p <0.001), age (r = 0.21, p <0.002) and BMI patients (r = 0.26, p <0.002) has been shown. There were no significant differences in the concentration of uric acid among patients receiving multiple antihypertensive agents.
The incidence of hyperuricemia demonstrated in this study confirms the findings of other authors and indicates a fairly common prevalence of this phenomenon among a population of patients with hypertension. Individually adjusted multidrug antihypertensive therapy does not seem to affect significantly the concentration of uric acid, but further research is needed in this respect.
高尿酸血症和痛风在全球范围内是日益严重的健康问题。其病因复杂,通常由尿酸生成过多和/或排泄受损引起。此外,一些用于治疗高血压的药物会增加高尿酸血症的风险。高尿酸血症的另一个危险因素是肥胖。尽管全球进行了大量研究,但目前对于无症状高尿酸血症患者的治疗尚无共识。
评估接受联合药物治疗的原发性高血压合并肥胖患者中高尿酸血症的患病率。
本研究共纳入109例肥胖患者(平均BMI = 34.6±3.5kg/m²),选自华沙红衣主教斯特凡·维辛斯基心脏病学研究所动脉高血压门诊。患者接受至少两种抗高血压药物治疗。测量患者的血压、尿酸和胰岛素水平。
平均收缩压和舒张压分别为131±5.9和84.6±3.6mmHg,平均尿酸水平为6.4±1.5mg/dl,平均胰岛素水平为17.6±11.0mU/L。33例患者(占受试者的27.5%)发现高尿酸血症。男性的尿酸水平明显更高。血清尿酸浓度与血清胰岛素(r = 0.27,p <0.001)、年龄(r = 0.21,p <0.002)和患者BMI(r = 0.26,p <0.002)之间存在正相关。接受多种抗高血压药物治疗的患者之间尿酸浓度无显著差异。
本研究中显示的高尿酸血症发病率证实了其他作者的研究结果,并表明该现象在高血压患者群体中相当普遍。个体化调整的多药联合抗高血压治疗似乎对尿酸浓度没有显著影响,但在这方面需要进一步研究。